The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Role of Bone-Modifying Agents in Metastatic Breast Cancer: An American Society of Clinical Oncology–Cancer Care Ontario Focused Guideline Update
Abstract
Purpose: To update, in collaboration with Cancer Care Ontario (CCO), key recommendations of the American Society of Clinical Oncology (ASCO) guideline on the role of bone-modifying agents (BMAs) in metastatic breast cancer. This focused update addressed the new data on intervals between dosing and the role of BMAs in control of bone pain. Methods: A joint ASCO-CCO Update Committee conducted targeted systematic literature reviews to identify relevant studies. Results: The Update Committee reviewed three phase III noninferiority trials of dosing intervals, one systematic review and meta-analysis of studies of de-escalation of BMAs, and two randomized trials of BMAs in control of pain secondary to bone metastases. Recommendations: Patients with breast cancer who have evidence of bone metastases should be treated with BMAs. Options include denosumab, 120 mg subcutaneously, every 4 weeks; pamidronate, 90 mg intravenously, every 3 to 4 weeks; or zoledronic acid, 4 mg intravenously every 12 weeks or every 3 to 4 weeks. The analgesic effects of BMAs are modest, and they should not be used alone for bone pain. The Update Committee recommends that the current standard of care for supportive care and pain management—analgesia, adjunct therapies, radiotherapy, surgery, systemic anticancer therapy, and referral to supportive care and pain management—be applied. Evidence is insufficient to support the use of one BMA over another. Additional information is available at www.asco.org/breast-cancer-guidelines and www.asco.org/guidelineswiki .
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Runowicz, C. D., Leach, C. R., Henry, N. L., Henry, K. S., Mackey, H. T., Cowens-Alvarado, R. L., Cannady, R. S., Pratt-Chapman, M. L., Edge, S. B., Jacobs, L. A., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.3809 · Cited by 1,071
How Quickly Do Systematic Reviews Go Out of Date? A Survival Analysis
Shojania, K. G., Sampson, M., Ansari, M. T., Ji, J., Doucette, S., & Moher, D. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-147-4-200708210-00179 · Cited by 838
Himelstein, A. L., Foster, J. C., Khatcheressian, J. L., Roberts, J. D., Seisler, D. K., Novotny, P. J., Qin, R., Go, R. S., Grubbs, S. S., O’Connor, T., et al. (2017) · JAMA · doi:10.1001/jama.2016.19425 · Cited by 356
Cited by
Adult Cancer Pain, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology
Swarm, R. A., Paice, J. A., Anghelescu, D. L., Are, M., Bruce, J. Y., Buga, S., Chwistek, M., Cleeland, C., Craig, D., Gafford, E., et al. (2019) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2019.0038 · Cited by 621
Medication-Related Osteonecrosis of the Jaw: MASCC/ISOO/ASCO Clinical Practice Guideline
Yarom, N., Shapiro, C. L., Peterson, D. E., Van Poznak, C. H., Bohlke, K., Ruggiero, S. L., Migliorati, C. A., Khan, A., Morrison, A., Anderson, H., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.01186 · Cited by 420
Self-citationBone metastasis: mechanisms, therapies, and biomarkers
Clézardin, P., Coleman, R., Puppo, M., Ottewell, P., Bonnelye, E., Paycha, F., Confavreux, C. B., & Holen, I. (2021) · Physiological Reviews · doi:10.1152/physrev.00012.2019 · Cited by 416
Metadata
- Authors
- Van Poznak, C., Somerfield, M. R., Barlow, W. E., Biermann, J. S., Bosserman, L. D., Clemons, M. J., Dhesy-Thind, S. K., Dillmon, M. S., Eisen, A., Frank, E. S., Jagsi, R., Jimenez, R., Theriault, R. L., Vandenberg, T. A., Yee, G. C., & Moy, B.
- Venue
- Journal of Clinical Oncology
- Published
- 2017-12-10
- Volume
- 35
- Issue
- 35
- Pages
- 3978-3986
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2765774285
- Cited by
- 182
- References
- 3
- FWCI
- 7.43
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Role of Bone-Modifying Agents in Metastatic Breast Cancer: An American Society of Clinical Oncology–Cancer Care Ontario Focused Guideline Update. https://app.cochat.ai/papers/10.1200/jco.2017.75.4614
- The paper
- Van Poznak, C., Somerfield, M. R., Barlow, W. E., Biermann, J. S., Bosserman, L. D., Clemons, M. J., Dhesy-Thind, S. K., Dillmon, M. S., Eisen, A., Frank, E. S., Jagsi, R., Jimenez, R., Theriault, R. L., Vandenberg, T. A., Yee, G. C., & Moy, B. (2017). Role of Bone-Modifying Agents in Metastatic Breast Cancer: An American Society of Clinical Oncology–Cancer Care Ontario Focused Guideline Update. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2017.75.4614
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.